Currently out of the existing stock ratings of Alan Carr, 76 are a BUY (93.83%), 3 are a HOLD (3.7%), 2 are a SELL (2.47%).

Alan Carr

Work Performance Price Targets & Ratings Chart

Analyst Alan Carr, carries an average stock price target met ratio of 67.99% that have a potential upside of 33.05% achieved within 380 days. Previously, Alan Carr worked at NEEDHAM.

Alan Carr’s has documented 169 price targets and ratings displayed on 27 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 12-May-2022.

Wall Street Analyst Alan Carr

Analyst best performing recommendations are on GNCA (GENOCEA BIOSCIENCES).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.

Average potential price target upside

of $421.2 (27.79%) on RGLS (REGULUS THERAPEUTICS).
of $114.8 (24.28%) on TTPH (TETRAPHASE PHARMACEUTICALS).
of $47.57 (66.08%) on GILD (GILEAD SCIENCES).

CRSP Crispr Therapeutics AG GILD Gilead Sciences MRNA Moderna PHAT Phathom Pharmaceuticals VRTX Vertex Pharmaceuticals ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd CARA Cara Therapeutic ICPT Intercept Pharmaceuticals LXRX Lexicon Pharmaceuticals TRVN Trevena TTPH Tetraphase Pharmaceuticals VIR Vir Biotechnology NBIX Neurocrine Biosciences RYTM Rhythm Pharmaceuticals VVUS VIVUS ZEAL Zealand Pharma A/S ADR AKAO Achaogen ALBO Albireo Pharma ARNA Arena Pharmaceuticals CDTX Cidara Therapeutics GNCA Genocea Biosciences NBRV Nabriva Therapeutics AG RGLS Regulus Therapeutics TBPH Theravance Biopharma TCDA Tricida

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Geoff Meacham (BAML)